Bisogamma

Quick links to important sections

Bisogamma

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisogamma

Property Description
Active ingredient Bisoprolol Fumarate
Form Film-coated tablets
Pharmacological class Cardioselective Beta-blocker (\beta1-antagonist)
General purpose Reduces cardiac workload and stabilizes heart rhythm
Origin Synthetic

Bisogamma: Identity, Classification, and Origin

Bisogamma is a synthetic, prescription-only medicinal product whose active ingredient is Bisoprolol Fumarate, classified as a beta-blocker. This substance is utilized as a core cardiovascular agent and is noted for its long-established use in supporting heart function. As a therapeutic entity, Bisogamma is manufactured for oral consumption and typically presented as a film-coated tablet, a form engineered for stable and consistent delivery of the medicine into the body, a key factor in its consistent clinical application.

What Type of Beta-Blocker is Bisogamma?

Bisogamma is pharmacologically classified as a selective \beta1-adrenergic receptor antagonist, commonly known as a cardioselective beta-blocker. This means the compound preferentially targets \beta1 receptors, which are predominantly found in the heart. This selectivity minimizes the impact on \beta2 receptors located elsewhere, such as in the lungs, offering a more focused therapeutic effect. Its mechanism of action also places it within a high-level therapeutic designation as a Class II antiarrhythmic agent, indicating its functional role in rhythm regulation.

General Purpose and Fundamental Action of Bisogamma

The general purpose of Bisogamma is to support the heart and circulatory system by easing the strain on the cardiac muscle. The medication functions by acting as a "brake" on the heart, mitigating the stimulating effects of stress hormones like adrenaline. This selective blocking action allows the heart to beat more steadily and efficiently, decreasing the overall cardiac workload. This regulated activity provides a foundational therapeutic benefit for managing chronic cardiovascular needs, such as ensuring the heart maintains an optimal rate under typical daily physical demands.

Regulatory References

  1. WHO Essential Medicines List (EML) - Bisoprolol
  2. WHO Essential Medicines List - Bisoprolol Entry
  3. EMA European Public Assessment Reports (EPAR)
  4. Public Assessment Report (PAR) - Bisoprolol (NL)

What side effects are possible with Bisogamma?

Possible Side Effects and Safety Information

The safety profile for Bisogamma (Bisoprolol Fumarate) is established through official regulatory documentation, which organizes possible adverse reactions by the frequency of their occurrence in clinical use.

Frequency-Classified Adverse Reactions

Side effects are categorized based on their official incidence rate:

Frequency Classification Examples of Officially Documented Adverse Reactions
Very Common (ge 1/10) Bradycardia (slow heart rate, specifically in chronic heart failure)
Common (ge 1/100 to <1/10) Dizziness, headache, fatigue, nausea, vomiting, diarrhoea, cold or numb extremities.
Uncommon (ge 1/1,000 to <1/100) Sleep disorders, depression, AV-conduction disturbances, bronchospasm (in susceptible patients).
Rare (ge 1/10,000 to <1/1,000) Syncope, nightmares, hallucinations, hepatitis, erectile dysfunction.

Time-Related Patterns and Serious Reactions

Many common effects—such as fatigue, dizziness, and headache—are noted to especially occur at the beginning of therapy and generally resolve within the first one to two weeks. A transient worsening of heart failure may occur during the dose titration period in chronic heart failure patients.

Serious adverse reactions officially documented include severe bradycardia, AV-conduction disturbances, and the potential for a severe exacerbation of angina pectoris or myocardial infarction if the medicine is stopped abruptly, particularly in patients with underlying coronary heart disease.

Population-Specific Safety Notes

The regulatory profile specifies that caution is advised for patients with severe renal or hepatic impairment. The drug may also mask symptoms of conditions like hypoglycaemia in patients with diabetes mellitus. For patients with bronchospastic diseases, such as asthma, an uncommon risk of bronchospasm is documented.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Bisogamma (Bisoprolol Fumarate) is officially defined by a set of profound physiological disturbances, demanding immediate emergency action as mandated by regulatory authorities.

Documented Clinical Manifestations

Overdosage is officially described by severe cardiovascular effects, including marked bradycardia (slow heart rate) and hypotension (low blood pressure). Other documented clinical signs include congestive heart failure, bronchospasm, and hypoglycemia (low blood sugar). Central nervous system effects such as drowsiness and confusion are also listed as manifestations.

Urgent Action and Severe Risk Profile

Regulatory documents identify severe outcomes like shock, convulsions (seizures), coma, and the risk of death. Due to this severe risk, government guidance requires that the individual seek immediate medical attention and call emergency services if the person has collapsed, had a seizure, or cannot be awakened. Bisoprolol Fumarate therapy must be stopped immediately in cases of suspected overdosage.

Management and Monitoring

Management protocols focus on symptomatic and supportive treatment. Procedures may involve the use of activated charcoal and administering intravenous fluids. Required hospital monitoring includes the continuous assessment of vital signs and an ECG (heart tracing). Regulatory documents note that the drug is not readily removed by dialysis. A specific population consideration is the heightened risk of hypoglycemia noted in the pediatric population following this type of overdose.

Therapeutic Uses of Bisogamma

Main Therapeutic Uses

Bisogamma is a medication containing the active substance bisoprolol, which belongs to a group of drugs known as beta-blockers. These medications primarily influence the heart and circulatory system by selectively blocking beta-1 receptors.

High Blood Pressure (Hypertension)

One of the primary indications for Bisogamma is the management of arterial hypertension. The medication helps lower blood pressure, which reduces the workload on the heart and helps prevent long-term damage to the blood vessels throughout the body.

Coronary Heart Disease

Bisogamma is used in the treatment of coronary heart disease, specifically chronic stable angina pectoris. In this condition, the heart muscle does not receive enough oxygen, often resulting in chest pain or pressure. By slowing the heart rate and reducing the force of contraction, the medication decreases the heart's oxygen requirement.

Chronic Heart Failure

Bisogamma is also indicated for the treatment of stable chronic heart failure. It is typically used as part of a comprehensive management plan to improve cardiac function over time. In this context, it helps the heart pump more efficiently and manages the symptoms associated with a weakened heart muscle.

Benefits and Mechanism of Action

Heart Rate Regulation

Bisogamma works by making the heart beat more slowly and regularly. By inhibiting specific stress signals to the heart, it prevents the heart from overworking during physical activity or emotional stress.

Cardiovascular Protection

Through the consistent control of blood pressure and heart rate, the medication assists in protecting vital organs from the complications of untreated cardiovascular conditions. This stabilization is a key benefit for patients with chronic cardiac imbalances.

Increased Physical Tolerance

For many patients, particularly those with angina or heart failure, the reduction in cardiac strain can lead to an improvement in their ability to engage in daily activities. By optimizing the balance between oxygen supply and demand in the heart, the medication helps maintain a more stable physical state.

Regulatory References

  1. Public Assessment Report of the European Medicines Evaluation Board

Eligibility and Restrictions for Use

Bisogamma is approved for use in adults aged 18 years and over for treating hypertension, angina pectoris, and stable chronic heart failure. Use is not recommended for children and adolescents under 18 due to a lack of therapeutic experience, a classification noted in regulatory documents.

The medicine is contraindicated and must not be used by individuals with severe acute conditions. These absolute prohibitions include acute heart failure, cardiogenic shock, second or third degree AV block (without a pacemaker), severe bronchial asthma, severe chronic obstructive pulmonary disease (COPD), metabolic acidosis, or known hypersensitivity to the active substance.

Eligibility is also restricted by specific conditions. Patients with severe hepatic impairment or severe renal impairment must adhere to a defined maximum daily dose limitation. Additionally, official regulatory labels state that Bisogamma is not recommended during pregnancy unless considered essential, and its use is discouraged during breastfeeding due to insufficient data on passage into breast milk. Use is specifically not established for the chronic heart failure indication in high-risk groups like those with Type I diabetes or a recent heart attack.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Bisoprolol Fumarate, the active ingredient in Bisogamma, are documented across several regulatory categories, primarily concerning additive effects on the cardiovascular system and changes to plasma concentration.

Officially, co-administration with Floctafenine and Sultopride is contraindicated, as these combinations pose a specific, increased risk of cardiovascular complications such as ventricular arrhythmia.

Other combinations are generally not recommended due to potential additive pharmacodynamic effects. This includes Verapamil-type and Diltiazem-type calcium antagonists and Class I antiarrhythmic drugs, as they may compound negative influences on heart rate and conduction.

Interaction Type Interacting Agent Official Regulatory Outcome
Metabolic Rifampicin May increase clearance, reducing Bisoprolol exposure.
Absorption Aluminum Hydroxide Decreases absorption; requires at least 2 hours separation of administration.
Pharmacodynamic NSAIDs May reduce the hypotensive effect of Bisoprolol.

For products that alter absorption, such as Aluminum Hydroxide and certain mineral supplements, the official labeling includes a mandatory time separation rule to ensure appropriate drug concentration. Alcohol (Ethanol) may increase the blood pressure-lowering effect. Furthermore, the official profile notes that patients with severe hepatic or renal impairment may be at a greater risk from drug interactions due to decreased elimination.

Mechanism of Action

Bisogamma acts by exerting a targeted influence on key regulatory systems within the cardiovascular and hormonal pathways. It attenuates sympathetic signaling to influence systemic cardiovascular dynamics.

Selective Reduction of Cardiac Signaling

This domain addresses the drug's primary action as a selective Beta-1 adrenergic receptor antagonist (beta1-AR). By blocking beta1-ARs on the heart, the drug reduces the binding and action of catecholamines, resulting in decreased heart rate (negative chronotropy) and reduced force of contraction (negative inotropy). This action reduces the kinetic and oxygen demand of the myocardium.

Modulation of the Renin-Angiotensin System (RAAS)

This mechanistic domain involves the drug's action on beta1-ARs in the kidneys. By engaging mechanisms that influence feedback regulation, Bisogamma inhibits the release of renin, initiating a cascade that modulates the RAAS pathway. This upstream action modulates hormonal signaling that contributes to peripheral vasoconstriction, resulting in decreased systemic vascular resistance.

Dosage and Administration Information

How to Use Bisogamma: Official Administration Guidelines

The usage of Bisogamma, which contains Bisoprolol Fumarate, is defined by guidelines focusing on oral administration and individualized dosing. The medicine is taken once daily in the morning, regardless of meals, as the film-coated tablet's absorption is not significantly affected by food. The tablet must be swallowed whole with liquid and must not be chewed, crushed, or split to ensure the controlled release of the active ingredient.


Administration Scope and Dosing

Bisogamma is used in long-term treatment protocols, and the starting dose and maximum dose are dependent on the specific condition being addressed.

Indication Starting Dose (Once Daily) Maximum Recommended Dose (Once Daily)
Hypertension & Angina 5 mg (may start at 2.5 mg) 20 mg
Stable Chronic Heart Failure 1.25 mg (Mandatory low start) 10 mg

Procedural Instructions and Adjustments

Treatment for Stable Chronic Heart Failure requires a mandated, gradual titration (step-wise dose increase) over several weeks under close clinical supervision to ensure tolerance is maintained. If the medication is used in patients with severe kidney (CrCl < 20 mL/min) or liver impairment, the dose generally should not exceed 10 mg once daily. If discontinuing treatment for any reason, the protocol requires the dose to be gradually reduced over a period of approximately one to two weeks; abrupt withdrawal is restricted to avoid exacerbation of the underlying condition. If a dose is missed, the standard procedure is to take it only if it is on the same day, otherwise it should be skipped; a double dose must never be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bisogamma

This overview summarizes the structure and reported findings of clinical research conducted for Bisogamma (Bisoprolol Fumarate). This information reflects group patterns observed under specific research conditions and is presented without offering medical advice or making claims about individual outcomes.

Evidence for use in Stable Chronic Heart Failure (HFrEF)

Research examined the use of this medication in adults whose chronic heart failure is stable and involves a reduced Left Ventricular Ejection Fraction (HFrEF). The evidence base includes large, long-term Randomized Controlled Trials (RCTs). These trials tracked outcomes like all-cause mortality and cardiovascular death. Data from major trials report patterns related to the rate of death and hospital admissions in the groups receiving the study medication compared to the placebo group. What remains uncertain is that few data are available on the use of this medication in patients whose heart failure involves a preserved LVEF (HFpEF).

Evidence for use in Elevated Blood Pressure (Hypertension)

For managing high blood pressure, research includes both short-term Randomized Controlled Trials (RCTs) and various observational studies. Studies explored outcomes related to physiological strain, such as changes in the patient's systolic and diastolic blood pressure readings, and heart rate. Studies report how symptoms evolved in the observed populations, describing patterns of reduction in blood pressure and heart rate. What is still uncertain is that follow-up durations were limited in many of the trials focused purely on blood pressure reduction.

Evidence in Special Populations and Uncertainties

The medication was evaluated in older adults, primarily as subgroups within larger heart failure trials, and research included different age groups, but sample sizes were modest for these specific analyses. Comparative evidence is lacking for children. For use during pregnancy, limited data are available or insufficient. The total body of evidence quality varies across studies, and research does not determine whether an individual will respond similarly to the average observed in the trials.

Key Studies & References

  1. Public Assessment Report - Bisoprolol Fumarate (Regulatory Efficacy/Safety Overview)

Frequently Asked Questions (FAQ)

Common questions about Bisogamma (FAQ)

Q: Is Bisogamma the same as other beta-blockers like Metoprolol or Atenolol?

A: Bisogamma's active ingredient, Bisoprolol Fumarate, is classified as a cardioselective beta1-blocker. This designation means it preferentially targets the beta-1 receptors found mainly in the heart. This specific mechanism is what distinguishes it from other types of beta-blockers.

Q: Does Bisogamma make you tired or sleepy?

A: Regulatory documents indicate that fatigue and dizziness are commonly reported side effects, especially when first starting the treatment. Less frequently, sleep disorders and, rarely, nightmares have also been documented. Patients experiencing persistent tiredness may wish to consult their healthcare provider.

Q: Is it normal to feel dizzy when first starting Bisogamma?

A: Yes, dizziness is listed in the official product information as a Common side effect. These common effects are noted to occur particularly at the beginning of therapy, often resolving within the first one to two weeks as the body adjusts to the medication.

Q: Can Bisogamma cause cold hands and feet?

A: Official safety documents confirm that cold or numb extremities (hands and feet) are a Common side effect of this medicine. This pattern is commonly observed with beta-blocker medications due to their effect on circulation.

Q: What should I do if I miss a Bisogamma dose?

A: Regulatory instructions generally advise taking a missed dose only if it is on the same day as the missed dose. If it is too late, the dose is usually skipped, and the next dose is taken at the usual time. Official instructions strongly caution against taking a double dose to make up for one that was missed.

Q: Is a slow heart rate normal when you are on Bisogamma?

A: A slower heart rate, or bradycardia, is a Very Common effect of the drug, particularly in patients being treated for chronic heart failure. This effect is a direct result of how the medicine works to reduce the strain on the heart, but regular monitoring of heart rate is a standard part of treatment with this medication.

Q: Does Bisogamma cause weight gain?

A: While not a common effect, unusual weight gain is listed in regulatory information as an uncommon but potentially serious side effect. Changes in weight are sometimes reported under metabolic side effects. Patients are generally advised to report significant, sudden changes in body weight.

Q: Can Bisogamma cause nightmares or sleep disturbances?

A: Official safety data indicates that sleep disorders are Uncommon, and nightmares are listed as a Rare side effect. These effects are not experienced by most people taking the medication.

Q: Does Bisogamma affect sexual function?

A: The official product information lists erectile dysfunction as a Rare side effect of the medication.

Q: Is Bisogamma often prescribed with other blood pressure medications?

A: Studies show that the active ingredient has been used effectively alone or in combination with other blood pressure medicines. For example, it has been used concomitantly with thiazide diuretics in clinical trials for hypertension.

Q: What research studies support the use of Bisogamma for heart conditions?

A: The use of this medication is primarily supported by large-scale Randomized Controlled Trials (RCTs). These studies tracked important patient outcomes such as all-cause mortality and cardiovascular death in groups of patients with stable chronic heart failure (HFrEF).

Q: Does Bisogamma affect blood sugar levels?

A: For individuals with diabetes, this medication may mask some common symptoms of hypoglycemia (low blood sugar), specifically a rapid pulse rate. Official safety information also notes that it may potentially cause changes in blood or urine sugar test results.

Q: What are the known severe side effects of Bisogamma?

A: Serious reactions documented include severe bradycardia (slow heart rate), AV-conduction disturbances, and the potential for a severe worsening of angina or heart attack if the medicine is suddenly stopped. This risk is why gradual discontinuation is required.

Q: Can I take ibuprofen or naproxen while on Bisogamma?

A: Regulatory warnings state that Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, may reduce the blood pressure-lowering effect of Bisoprolol. Patients are advised to ensure their healthcare provider is aware of all concomitant medications.

Q: Is it necessary to monitor blood pressure while on Bisogamma?

A: Since the drug's primary action is to lower blood pressure and heart rate, regular medical check-ups are standard practice to monitor that the treatment is effective and well-tolerated.

Q: Is Bisogamma a long-term treatment or just for a short time?

A: According to the official product literature, treatment with the active ingredient Bisoprolol Fumarate is typically considered prolonged (long-term) for its approved cardiovascular indications.

Q: Can Bisogamma cause hair loss?

A: Hair loss, or alopecia, has been documented as a Very Rare side effect of the medication, affecting less than 0.01% of users according to safety data.

Q: How often do I need follow-up appointments when taking Bisogamma?

A: Official guidelines emphasize the importance of regular medical check-ups, which are particularly important during the initiation of therapy and when the dosage is being adjusted.

Q: Are there any common skin reactions associated with Bisogamma?

A: Regulatory data documents common skin reactions such as pruritus (itching). Less frequent reactions, including rash, flushing, and exacerbation of psoriasis, have also been listed.

Q: Does Bisogamma cause dry mouth?

A: Dry mouth has been documented in official reports as a common side effect of the medication.

Q: Are there any specific lab tests needed before starting Bisogamma?

A: Caution is advised for patients with severe kidney or liver impairment. Therefore, monitoring relevant kidney and liver function tests may be necessary before and during treatment, as reflected in regulatory warnings.

Q: How long does Bisogamma stay in your system?

A: According to the pharmacokinetics data, the drug's elimination half-life ranges from approximately 9 to 12 hours. This duration is a key factor in how long the active effects of the drug are sustained.

Q: Are there restrictions on driving or operating machinery while taking Bisogamma?

A: Because the medicine can cause side effects like dizziness and fatigue, official patient information suggests caution may be warranted when driving or operating machinery until the patient knows how the drug affects them.

Q: Can you take Bisogamma if you have Reynaud's phenomenon?

A: Official safety information advises caution, as beta-blockers are known to cause cold extremities and may potentially worsen symptoms of peripheral circulatory disturbances like Reynaud's phenomenon.

How should Bisogamma be stored and disposed of?

How to Store and Dispose of Bisogamma

Bisogamma (Bisoprolol Fumarate) must be stored under specific conditions to maintain its stability and effectiveness, as directed by official regulatory labeling.


Storage Requirements

The medicine requires storage at Controlled Room Temperature (CRT), typically defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and light and should be kept in the original, tightly closed container.

It is mandatory to store Bisogamma out of the sight and reach of children.


Disposal Instructions

Unused or expired Bisogamma should not be disposed of in household waste or flushed down the toilet (wastewater), as this can contaminate the environment. The product must be discarded through a designated take-back program or returned to a pharmacy, in compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisogamma found in:

A-Z Index: